“…Neuronal differentiation Cañon et al, 2004;Scheibe et al, 1991;Scheibe and Wagner, 1992 NT2 Edsjo et al, 2003;Encinas et al, 1999Encinas et al, , 2000Kaplan et al, 1993;Rossino et al, 1991;Wuarin et al, 1994 MN9D Bain et al, 1995;Gottlieb and Huettner, 1999;O'Shea, 2001;Bibel et al, 2004;Guan et al, 2001 Novitch et al, 2003;Sockanathan et al, 2003;Sockanathan and Jessell, 1998 Edsjo et al, 2003;Kaplan et al, 1993;Lucarelli et al, 1995;Malek and Halvorsen, 1997;Merrill et al, 2002Merrill et al, , 2005Rossino et al, 1991 P19 cell line Stra1, Stra3 and more Bouillet et al, 1995;Oulad-Abdelghani et al, 1997 RARs, RXRs, nuclear matrix associated protein; synergistic effects with neurotrophins and more Cheung et al, 2000aCheung et al, ,b, 2005Cheung and Ip, 2000;Wuarin et al, 1994 PC3 human prostate carcinoma cell line IGFBP-3, -5 (up) Hwa et al, 1997 F9 embryonal carcinoma cell line FGF-3 (up) Murakami et al, 1999 Myeloma cells, osteoblasts IL-6, IL-6R (down) Chen et al, 1999;Smith et al, 1998;refs. expression of IL-6 is suppressed or enhanced depending on the cell culture system. While the production of IL-1 itself may be supported by retinoids, RA counteracts downstream effects, for instance the IL-1-induced synthesis of other cytokines (Gross et al, 1993).…”